Kornimate/medical-research-clean huggingface dataset:
to examine if the mother's glucose levels and glucose levels in the blood can predict cord hypoglycemia in newborns at risk.

Conditions: Neonatal Hypoglycemia

Summary: background neonatal hypoglycemia is one of the most common metabolic disorders in neonatology. maintaining stable levels of glucose in the transition from fetal life to life after birth is very important. yet, except for the recognizing of at-risk populations, there are not many individual measures which can help and predict which newborns (from at-risk populations) will develop hypoglycemia and which will not. objective our objective is to try to characterize by the mother's glucose levels at birth and by umbilical cord glucose levels who would be at increased risk of hypoglycemia in the hours after birth in the population that is at increased risk of this complication in advance.

background neonatal hypoglycemia is one of the most common metabolic disorders in neonatology. maintaining stable levels of glucose in the transition from fetal life to life after birth is very important. yet, except for the recognizing of at-risk populations, there are not many individual measures which can help and predict which newborns (from at-risk populations) will develop hypoglycemia and which will not. objective our objective is to try to characterize by the mother's glucose levels at birth and by umbilical cord glucose levels who would be at increased risk of hypoglycemia in the hours after birth in the population that is at increased risk of this complication in advance. patients \& methods all women who arrived to the delivery room at lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because his affiliation to the at-risk population including: delivery below 37th week, maternal diabetes during pregnancy and newborns in weight under percentile 10 or above percentile 90 by dolberg graphs.

Eligibility criteria:
inclusion criteria: 1. single pregnancy 2. vaginal or cesarean birth. 3. births where there is an indication of neonatal hypoglycemia follow-up - one or more of the following: * delivery week below 37 full weeks. * maternal diabetes during pregnancy (gestational diabetes or pre-gestational). * newborn under percentile 10 by dolberg graph. * newborn above percentile 90 by dolberg graph. exclusion criteria: 1. multiple pregnancy 2. pregnancies in which there is no indication for routine monitoring of glucose levels after birth
risk factors for pregnancy-induced hypertension in pregnant patients undergoing cesarean section

Conditions: Adverse Maternal and Neonatal Outcomes

Summary: after institutional review board approval, we performed a retrospective cohort study among all women presenting for pregnancy-induced hypertension under cesarean section in renji hospital affiliated to shanghai jiaotong university from january 2013 to january 2020.perioperative data were collected, including preoperative general condition, laboratory examination, auxiliary examination (blood routine, blood coagulation, liver and kidney function, electrocardiogram, cardiac ultrasound, etc.), perioperative indicators, postoperative laboratory examination (blood routine, blood coagulation, liver and kidney function, etc.), postoperative follow-up and satisfaction survey of patients.


Eligibility criteria:
inclusion criteria: * all women presenting for pregnancy-induced hypertension in renji hospital affiliated to shanghai jiaotong university from january 2013 to january 2020 cesarean section operation exclusion criteria: * no
cytokeratin 8 level in age-related macular degeneration

Conditions: Age-related Macular Degeneration

Summary: the investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (amd) before therapy with intravitreal ranibizumab, and identify associations with visual and anatomical outcome after treatment.

in this non-randomized, and open-label study, the investigators will prospectively evaluate 58 patients with treatment naive exudative age-related macular degeneration (amd) who receive intravitreal ranibizumab injection. a mean volume of 0.1 ml of aqueous humor samples will be taken each time an intravitreal injection is indicated and performed. cytokeratin 8 level in aqueous humor will be evaluated, and associations of baseline cytokeratin 8 level and visual (the best corrected visual acuity change) and anatomical (optical coherence tomography parameters) after ranibizumab injection will be investigated.

Eligibility criteria:
inclusion criteria: 1. treatment-naive neovascular amd patients requiring intravitreal injection of ranibizumab 2. a recent onset of disease confirmed by history and clinical findings. 3. patient is required to be least 50 years of age exclusion criteria: 1. myopia with a refractive error \>-3.0 diopters or evidence of pathologic myopia (pre-operative refractive data were used to assess pseudophakic eyes) 2. any history of vitrectomy, anti-vegf therapy, or photodynamic therapy (pdt) 3. history of cataract surgery within 3 months prior to presentation 4. evidence of end-stage amd such as subfoveal fibrosis or atrophy 5. evidence of other retinal diseases including central serous chorioretinopathy and other neovascularmaculopathies; glaucoma; poor imaging data caused by media opacity; or unstable fixation 6. patients with uncontrolled systemic diseases, use of immunosuppressive drugs, or malignant tumors of any location

Keywords: keratin ranibizumab
pennsylvania idiopathic pulmonary fibrosis research registry

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the pennsylvania idiopathic pulmonary fibrosis state-wide research registry (pa-ipf) is a cooperative project between five medical centers to coordinate a team of investigators. the aim of this registry will be: 1) to assess the extent of lung fibrosis in the commonwealth of pennsylvania 2) to provide better access of patients with pulmonary fibrosis in all regions of pennsylvania to standard of care and diagnosis 3) to facilitate the translation of new therapeutic interventions from the bench to the bedside.

the university of pittsburgh medical center, dorothy p. \& richard p. simmons center for interstitial lung disease is the coordination center for the pennsylvania idiopathic pulmonary fibrosis statewide research registry, the collaborative institutions include: the university of pennsylvania health system, geisinger health system, and penn state milton s. hershey medical center. the pa-ipf registry developed into a web site that contains information for patients, health professionals, and families, as well as an internet-based database that will store information about patients to provide them with guidance about care, research, and support groups close to the area in which they live. benefits for membership in the pa-ipf registry include: * staying informed about ipf research news, both nationally and locally. * having advance notice of any ipf research in which patients may be eligible to participate.

Eligibility criteria:
inclusion criteria: * ipf diagnosis * sufficient testing results completed for an ipf diagnosis (screening script) * adults (age \> 18 years old) * participants who read and comprehend english language exclusion criteria: * children * prisoner-patients

Keywords: idiopathic pulmonary fibrosis interstitial lung disease
glp1r-imaging in post-rygb hypoglycemia

Conditions: Obesity; Hypoglycemia Post Gastric Bypass Surgery; Hyperinsulinemic Hypoglycemia

Summary: in order to evaluate the difference in beta cell mass in patients with and without hyperinsulinemic hypoglycemia after roux en y gastric bypass (rygb) investigators aim to compare quantitative pet imaging of the pancreas between these patient groups. these highly relevant data will provide investigators with more information on the possible role of beta cell mass in the mechanisms of hyperinsulinemic hypoglycemia bariatric surgery.


Eligibility criteria:
inclusion criteria: * signed informed consent patients: - persisting hyperinsulinemic hypoglycemia after a low-carbohydrate diet and/or insulin suppressive medication for one year. controls: * rygb at least 2 years ago * normal glucose levels before and after rygb (fasting glucose between 4 and 6 mmol/l or hba1c between 20 and 42 mmol/mol) * score ≤ 7 on sigstad's scoring system (table 1) * hypoglycemia excluded by 14-day continuous glucose monitoring * individual matched to hh group on age (± 5 years), sex and bmi at time of inclusion (± 2 kg/m2) exclusion criteria: * anti-diabetic medication in the past 6 months * treatment with synthetic exendin (exenatide, byetta®) or dipeptidyl-peptidase iv inhibitors in the past six months. * known liver failure or serum liver values over 2 times normal value at the time of standard laboratory assessment. normal values of total bilirubin, γ-gt, asat and albumin are \<21 μmol, \<40 u/l, \<30 u/l and 35-50 g/l respectively * pregnancy or the wish to become pregnant within 6 months * breast feeding * kidney failure, i.e. calculated creatinine clearance below 40 ml/min * age \< 18 years * no signed informed consent
l-arginine and erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the purpose of the study is to determine whether the treatment with l-arginine leads to an improvement of erectile dysfunction in patients with erectile dysfunction.

erectile dysfunction (ed) is a common medical disorder often affecting the aging male. nitric oxide (no) is a physiological signal essential to penile erection. no synthase (nos) catalyzes the production of no from l-arginine. adma, a competitive inhibitor of no synthase increases with age and many disorders that reduce no in the erectile tissue are commonly associated with ed. although new pharmacological strategies have been identified for medical treatment of ed, patients often seek alternative therapies for cost or side effect reasons. the aim of the present study is to determine the efficacy of orally administered l-arginine on ed not caused by established organic disease.

Eligibility criteria:
inclusion criteria: * patients age between 20 and 65 years, an ed for at least 6 months duration and written consent. * each patient had to be informed about the study details in written and oral form before the beginning of the drug administration. * the hormonal status including dehydroepiandrosterone sulfate (dheas), prolactin and testosteron of each patient had to be within the normal range. - exclusion criteria: * patients with primary erectile dysfunction, congenital anomalies, diabetes mellitus, severe hepatic-and renal insufficiency, severe cardiovascular diseases, cerebrovascular accidents, uncontrolled hypertension, endocrine diseases, psychiatric disorders, and evidence of dementia were excluded. * patients were excluded if they had pelvic fractures or prostatectomy and if they had undergone reconstructive or prosthetic surgery on the penis. * increased levels of serum potassium, known hypersensitivity to the study medication or any ingredient of the drug. * administration of pde-5-inhibitors (sildenafil, tadalafil, vardenafil or apomorphine) within four weeks prior to the administration of l-arginine or placebo led to exclusion.

Keywords: nitrate nitric oxide asymmetric dimethylarginine blood pressure nos iief
lorlatinib-related hyperlipidemia in alk+ non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer; Hyperlipidemia

Summary: the goal of this observational study is to learn about the long-term effects of lorlatinib related hyperlipidemia in nsclc patients who take lorlatinib for at least 21 days. the main question it aims to answer is: * whether blood lipids have been lowered down to an anticipated level within recommended range after the initial revealed lorlatinib related hyperlipidemia? * will it be harmful to the cardiovascular system when blood lipids were not lowered down to normal levels in these cancer patients treated with lorlatinib, i.e. major adverse cardiac events (mace), or instead, carotid artery intima-media thickness. participants already taking lorlatinib as part of their regular medical care for nsclc will answer online survey questions.


Eligibility criteria:
inclusion criteria: * advanced alk+ nsclc diagnosed by patholgy and/or cytology * ecog 0-2 * age 18-80 years * taken lorlatinib for at least 20 days * signed informed consent. exclusion criteria: * treatment with other anti-cancer drugs during lorlatinib treatment

Keywords: nsclc hyperlipidemia lorlatinib
early screening for gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus

Summary: the working hypothesis of this proposal is that screening for gestational diabetes mellitus as early as the 1st trimester is efficient for detecting the forthcoming presence or absence of gestational diabetes mellitus. the investigators long-term goal is the prevention of gestational diabetes mellitus onset i.e. the prevention of progression to gestational diabetes mellitus, in order to enable delivery of appropriate counselling, diagnostics and treatment for pregnant women, as well as to improve pregnancy outcomes. therefore, robust 1st trimester screening criteria is needed. the overall objective of this proposal is to determine an accurate and valid 1st trimester 1h post 50g oral glucose challenge test plasma glucose cut-off value that is predictive of gestational diabetes mellitus onset.


Eligibility criteria:
inclusion criteria: * age \> 18 yrs * gestational age between 6 and 13 weeks from last menstrual period, * alcohol \< 2 drinks/day * not involved in regular high intensity physical activity * singleton pregnancy * otherwise good health status. exclusion criteria: * type 1 or type 2 diabetes * taking drugs interfering with glucose metabolism
shared online health records for patient safety and care

Conditions: Diabetes

Summary: the study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology. hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.

during the first phase of the study, primary care practice patients continue to receive "usual care" while their physician's offices are using patient gateway, an internet portal offering secure messaging, common requests, chart information, and health information that has already been developed. also in this first phase, all patients using patient gateway will receive an electronic letter explaining the research study and a link to an electronic consent form. in addition to recruitment of subjects, phase 1 allows for baseline data to be collected. in the second phase, study clinics will be randomized into one of two intervention "arms". study subjects whose clinics are randomized into arm 1 will be invited to review and comment on their medication, allergy, and diabetes information through patient gateway; they can then submit this information to their primary care physician for review. those randomized into arm 2 will report on their health maintenance status and family history and submit this information to their primary care physician through patient gateway prior to a scheduled visit. chart reviews performed at the end of phase 1 and phase 2 will be conducted to identify differences in process measures and outcome measures between intervention and control groups. in addition, a medication phone survey sub-study will be conducted to evaluate the effect of the new patient gateway features on medication management.

Eligibility criteria:
inclusion criteria: * all patients, who are enrolled in patient gateway, of physicians and practices participating in the study. exclusion criteria: * any patients who are not enrolled in patient gateway or do not belong to a participating practice.

Keywords: patient portals electronic health records family history health maintenance medications diabetes
risk factors for asymptomatic rotator cuff tears to become symptomatic.

Conditions: Rotator Cuff Tears

Summary: in this prospective study, subjects older than 55 years with a degenerative asymptomatic rotator cuff tears will be followed for a period of 2 years. after testing, a symptom registration form will be filled in every 3 months. the test moment consists of pain measurements (pain pressure thresholds and conditioned pain modulation), biomechanical measurements (strength (including hand grip strength), range of motion, ultrasound (while measuring electromyographic activity) and shear wave elastography) and psychosocial measurements (psychosocial questionnaires).

in this prospective study, the aim is to determine the risk factors for developing a symptomatic rotator cuff (rc) tear. it is still unknown why some patients with a rc tear develop complaints and others do not. better understanding of the etiological factors that underlie rc pathology will increase the efficacy of early clinical intervention. a prospective study with a minimum of 2 year follow-up will be conducted. biomechanical, psychosocial and painrelated factors will be screened as possible risk factors. we hypothesize that negative psychosocial factors and biomechanical impairments will be risk factors for an asymptomatic tear to become symptomatic over time.

Eligibility criteria:
inclusion criteria: * 55+ years old * male or female * asymptomatic rotator cuff tear diagnosed with ultrasound by a medical doctor * mean visual analogue score (vas) of \< 3 during daily life activities * no shoulder complaints having a significant influence on daily life activities exclusion criteria: * recent shoulder trauma * massive rotator cuff tears * small partial thickness tears * neck complaints * history of shoulder surgery * history of proximal upper arm fracture * frozen shoulder * inflammatory arthritis * peripheral or central disorders * cognitive disorders

Keywords: asymptomatic rotator cuff tears symptom registration observational study
effect of continuous positive airway pressure delivered by two different modalities on breathing pattern in preterm infants

Conditions: Continuous Positive Airway Pressure

Summary: in this study, the investigators want to observe how continuous positive airway pressure delivered by two different modalities affects breathing pattern in small preterm infants. using a specialized feeding tube in the stomach, the investigators can measure and compare how the diaphragm (a large breathing muscle) might be affected by those two modalities.

many preterm very low birth weight infants require continuous positive airway pressure(cpap) for breathing support because of lung immaturity. cpap can be delivered by the infant flow(tm) device which is well studied. prolonged use of nasal prongs cpap has been shown to cause discomfort and, rarely, nasal injury leading to long term disfigurement. on the other hand, high flow nasal cannula (hfnc) ,which is another modality of delivering cpap, creates less pressure on the nose and less disfiguring effect but previous research showed that the use of hfnc may be less effective than if-cpap in providing breathing support in these infants. we plan to study 10 stable preterm infants born less than 32 weeks' gestation and 1.5 kilograms at birth after being stable for at least 48hours on if-cpap. babies will be randomized to start on if-cpap or hfnc for 30 minutes. after 45 minutes of adaptation, baby will be switched to the other modality for another 30 minutes. by inserting a specialized feeding tube with sensors into the stomach, we can measure the electrical activity of the diaphragm (eadi). by analysing eadi with each modality of delivering cpap, we want to directly assess how hfnc affects breathing compared to if-cpap.

Eligibility criteria:
inclusion criteria: * birth weights ≤ 1500g * gestational age less than 32 week * stable on nasal continuous positive airway pressure (cpap) of 5-6cmh20 support for at least 48 hours * treated with methylxanthines for apnea of prematurity * in less than 35% oxygen exclusion criteria: * congenital and acquired problem of the gastrointestinal tract * phrenic nerve injury and/or diaphragm paralysis * esophageal perforation/tracheoesophageal fistula * congenital/acquired neurological deficit and/or seizures * hemodynamic instability * congenital heart disease (including symptomatic patent ductus arteriosus) * undergoing treatment for sepsis or pneumonia * use of muscle relaxants, narcotic analgesics, or gastric motility agents * congenital anomalies of respiratory tract (e.g. ccam) * infants requiring more than 35% oxygen * infants with facial anomalies * infants with pneumothorax and/or pneumomediatinum * infants in the immediate postoperative period * infants with significant gastric residues and vomiting

Keywords: infant, premature infant, very low birth weight diaphragm apnea continuous positive airway pressure
the peng block in elective hip surgery and its effect on postoperative pain and length of stay.

Conditions: Pain, Postoperative

Summary: effective postoperative pain management in elective hip surgery is crucial for the patients well-being, rapid mobilisation and potential reduction of length of stay. in addition to standard intravenous pain medication, anaesthetic blocks are reportedly effective. recently, the peng block, a pericapsular pain block without impairment of the motor function has been introduced in literature and performed at the investigator's hospital (hfr fribourg, switzerland) for total hip arthroplasty and surgical hip dislocation - the two most commonly performed elective hip surgeries. as high-quality evidence on the effectiveness of this novel block is lacking, the investigator's objective is to evaluate the effectiveness of (1) patient-reported pain reduction, (2) total consumption of postoperative morphine, and the length of stay at the hospital.

forty patients undergoing total hip arthroplasty and 40 patients undergoing surgical hip dislocation will be enrolled in a prospective, double-blind, controlled trial performed at the investigator's hospital. this study will be the first prospective study evaluating the potential of this pain block in elective hip surgery potentially affecting both patients' postoperative well-being and optimizing costs of the hospital by reducing length of stay.

Eligibility criteria:
inclusion criteria: * anterior total hip arthroplasty for hip osteoarthritis * surgical hip dislocation for femoro-acetabular impingement (type cam-/pincer) * age 16-85 years * american society of anesthesiologists (asa) physical status 1 to 3 exclusion criteria: * patient refusal/no informed consent * inability to give informed consent * lateral approach for total hip arthroplasty * bilateral procedure * additional osteotomies of the femur and/or acetabulum * previous hip \& pelvis surgery * chronic opioid users * known allergy or intolerance to medications used in the trial (local anesthetic, opioid) * infection at the injection site * body mass index \> 40kg/m2 * spinal anesthesia

Keywords: peng block postoperative pain elective hip surgery total hip arthroplasty surgical hip dislocation